723 related articles for article (PubMed ID: 34167573)
41. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
42. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
[TBL] [Abstract][Full Text] [Related]
43. Increase of Tumor Infiltrating γδ T-cells in Pancreatic Ductal Adenocarcinoma Through Remodeling of the Extracellular Matrix by a Hyaluronan Synthesis Suppressor, 4-Methylumbelliferone.
Suto A; Kudo D; Yoshida E; Nagase H; Suto S; Mimura J; Itoh K; Hakamada K
Pancreas; 2019 Feb; 48(2):292-298. PubMed ID: 30589828
[TBL] [Abstract][Full Text] [Related]
44. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
45. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.
Burrack AL; Rollins MR; Spartz EJ; Mesojednik TD; Schmiechen ZC; Raynor JF; Wang IX; Kedl RM; Stromnes IM
J Immunol; 2021 Mar; 206(6):1372-1384. PubMed ID: 33558374
[TBL] [Abstract][Full Text] [Related]
46. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
47. Neuromedin U regulates the anti-tumor activity of CD8
Zheng R; Wang S; Wang J; Zhou M; Shi Q; Liu B
Cancer Sci; 2024 Feb; 115(2):334-346. PubMed ID: 38071753
[TBL] [Abstract][Full Text] [Related]
48. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
49. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
50. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer.
Blise KE; Sivagnanam S; Betts CB; Betre K; Kirchberger N; Tate BJ; Furth EE; Dias Costa A; Nowak JA; Wolpin BM; Vonderheide RH; Goecks J; Coussens LM; Byrne KT
Cancer Immunol Res; 2024 May; 12(5):544-558. PubMed ID: 38381401
[TBL] [Abstract][Full Text] [Related]
51. Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer.
Mehra S; Garrido VT; Dosch AR; Lamichhane P; Srinivasan S; Singh SP; Zhou Z; De Castro Silva I; Joshi C; Ban Y; Datta J; Gilboa E; Merchant NB; Nagathihalli NS
Cancer Res Commun; 2023 Jul; 3(7):1224-1236. PubMed ID: 37448553
[TBL] [Abstract][Full Text] [Related]
52. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
54. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Liu Q; Wu H; Li Y; Zhang R; Kleeff J; Zhang X; Cui M; Liu J; Li T; Gao J; Pan B; Wu W; Wang W; Zhou L; Guo J; Dai M; Zhang T; Liao Q; Lu Z; Zhao Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
[TBL] [Abstract][Full Text] [Related]
55. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
Mace TA; Shakya R; Elnaggar O; Wilson K; Komar HM; Yang J; Pitarresi JR; Young GS; Ostrowski MC; Ludwig T; Bekaii-Saab T; Bloomston M; Lesinski GB
Oncotarget; 2015 Dec; 6(42):44509-22. PubMed ID: 26575024
[TBL] [Abstract][Full Text] [Related]
56. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
Arensman MD; Telesca D; Lay AR; Kershaw KM; Wu N; Donahue TR; Dawson DW
Mol Cancer Ther; 2014 Oct; 13(10):2303-14. PubMed ID: 25082960
[TBL] [Abstract][Full Text] [Related]
57. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Byrne KT; Vonderheide RH
Cell Rep; 2016 Jun; 15(12):2719-32. PubMed ID: 27292635
[TBL] [Abstract][Full Text] [Related]
58. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.
Awasthi N; Mikels-Vigdal AJ; Stefanutti E; Schwarz MA; Monahan S; Smith V; Schwarz RE
J Cell Mol Med; 2019 Jun; 23(6):3878-3887. PubMed ID: 30941918
[TBL] [Abstract][Full Text] [Related]
60. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy.
Miyake K; Mori R; Homma Y; Matsuyama R; Okayama A; Murakami T; Hirano H; Endo I
J Surg Res; 2017 Dec; 220():391-401. PubMed ID: 29180208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
